A predictive factor for the response to s-1 plus cisplatin in gastric cancer

World Journal of Gastroenterology

Volumn 16, Issue 36, 2010, Pages 4575-4582

  Miyazaki, Ikuko ^a   Kawai, Takashi ^a   Harada, Youji ^b   Moriyasu, Fuminori ^a  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b Toda Chuo General Hospital   (Japan)

Author keywords

Biopsy; Dihydropyrimidine dehydrogenase; Gastric cancer; Orotate phosphoribosyltransferase; Thymidylate synthase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG METABOLISM; ENDOSCOPIC BIOPSY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; STOMACH CANCER; TREATMENT RESPONSE;

EID: 77957563053     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i36.4575     Document Type: Article

References (23)

1. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y, Gotoh M. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89: 2207-2212
2. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58: 191-197
3. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-237
4. Beck A, Etienne MC, Chéradame S, Fischel JL, Formento P, Renée N, Milano G. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30A: 1517-1522
5. Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F, Milano G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-1670
6. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H, Fukushima M. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 1999; 5: 883-889
7. Ususyo N, Yoshida M, Akimoto S, Yano K, Fujiwara R, Yautida S, Hagiike M, Deishi K, Aida F, Okada S, Maeda H. Prediction of effects and side effects of fluoropyrimidine administered for gastric cancers and criteria of drug selection: Jpn J Cancer Clin 2004; 50: 473-479
8. Kurebayashi J, Yamamoto Y, Udagawa K, Okubo S, Fukushima M, Sonoo H. Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyriminide dehydrogenase in cancer tissues. Oncol Rep 2004; 11: 973-979
9. Japanese classification of gastric carcinoma--2nd English edition--response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer 2001; 4: 1-8
10. Ishida H, Shirakawa K, Ohsawa T, Sobajima J, Hayashi Y, Nakada H, Yokoyama M, Hashimoto D. [Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment] Gan To Kagaku Ryoho 2005; 32: 1929-1934
11. Koizumi W, Kurihara M, Nakano S, Hasegawa K. PhaseII study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000; 58: 191-197
12. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000; 83: 141-145
13. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56: 2602-2606
14. Ichikawa W, Takahashi T, Sudo K, Mituyoshi S, Yamashita T, Sirota Y, Nihei Y, Hirayama K. Predictive values of thymidine synthase and dehydropyrimidine dehydrogenase gene expression in gastric cancer patients treated with S-1 based chemotherapy. Jpn J Cancer Clin 2003; 49: 599-560
15. Amatori F, Di Paolo A, Del Tacca M, Fontanini G, Vannozzi F, Boldrini L, Bocci G, Lastella M, Danesi R. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Pharmacogenet Genomics 2006; 16: 809-816
16. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-1327
17. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24: 4069-4077
18. Honda J, Sasa M, Moriya T, Bando Y, Hirose T, Takahashi M, Nagao T, Tangoku A. Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results. J Med Invest 2008; 55: 54-60
19. Harada K, Kawashima Y, Yoshida H, Sato M. Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1. Oncol Rep 2006; 15: 1417-1423
20. Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, Sasaki Y, Hirayama R. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 2006; 119: 1927-1933
21. Shimizu T, Yamada Y, Yasui H, Shirao K, Fukuoka M. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine. Anticancer Res 2005; 25: 2997-3001
22. Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD, Fukushima M. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 2008; 22: 709-716
23. Koga M, Anegawa E, Yoh J, Tsuyama H, Sakaino H, Iwamoto O, Koga C, Kusukawa J. Clinical relevance of thymidylate synthase (TS) activity for S-1-based chemotherapy in squamous cell carcinoma of the oral cavity. Br J Oral Maxillofac Surg 2010; 48: 88-93